The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
LLM 2021 | The role of transplant in MCL in the era of cellular therapy
Natalie Grover, MD, UNC School of Medicine, Chapel Hill, NC, comments that allogeneic transplant still has a role in mantle cell lymphoma (MCL) because there are not enough long-term data on the duration of the remission after CAR T-cell treatment. In young, fit patients, the longer follow-up after treatment shows durable remissions and supports the use of allogeneic transplant as an option, but preferably after CAR T-cell treatment relapse since its results are promising, and the toxicity rates are lower. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Consulting: Tessa and Novartis
Advisory board: ADC therapeutics and Kite
Research funding: Genentech
